Use of combinations of antipsychotics: McLean Hospital inpatients, 2002

被引:32
作者
Centorrino, F
Fogarty, KV
Sani, G
Salvatore, P
Cincotta, SL
Hennen, J
Guzzetta, F
Talamo, A
Saadeh, MG
Baldessarini, RJ
机构
[1] McLean Hosp, Schizophrenia & Bipolar Disorder Res Program, Belmont, MA 02478 USA
[2] McLean Hosp, Psychopharmacol Programs, Belmont, MA 02478 USA
[3] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA
[5] Univ Parma, Dept Neurosci, Sect Psychiat, I-43100 Parma, Italy
关键词
antipsychotics; combination; polytherapy; polypharmacy; schizophrenia; bipolar disorder;
D O I
10.1002/hup.719
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The empirical use of combinations of antipsychotic agents appears to be increasing with little research support for the relative efficacy, safety or cost-effectiveness of this practice. Such treatment was evaluated in hospitalized psychiatric patients. Methods Samples of consecutive inpatients treated with > 2 ('polytherapy') vs 1 antipsychotic ('monotherapy') were matched on age, sex, diagnosis and admission clinical ratings, and these groups were compared on total daily chlorpromazine-equivalent doses, days in hospital, and changes in clinical ratings between admission and discharge. Results The study sample included 69 polytherapy and 115 well-matched monotherapy subjects. Despite matching for initial CGI and GAF ratings, polytherapy was associated with high PANSS subscale scores of positive symptoms among affective psychosis, and relatively greater PANSS subscale ratings of excitement-agitation among patients diagnosed with schizophrenia. Estimated clinical improvement during hospitalization was similar among poly- and monotherapy patients, but total daily CPZ-eq doses at discharge averaged twice-greater with polytherapy, and hospitalization lasted 1.5 times longer. Conclusions Antipsychotic polytherapy as well as the types of agents combined may reflect clinician responses to particular symptom patterns. The value of specific combinations of antipsychotic agents and their comparison with monotherapies requires specific, prospective, randomized and well-controlled trials that consider matching on clinical characteristics and truly comparable doses across regimens. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:485 / 492
页数:8
相关论文
共 27 条
[1]  
[Anonymous], 1999, J Clin Psychiatry, V60 Suppl 11, P3
[2]  
Bacher NM, 1996, AM J PSYCHIAT, V153, P137
[3]  
Baldessarini R. J., 2005, GOODMAN GILMANS PHAR
[4]   Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits [J].
Centorrino, F ;
Goren, JL ;
Hennen, J ;
Salvatore, P ;
Kelleher, JP ;
Baldessarini, RJ .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (04) :700-706
[5]   Inpatient antipsychotic drug use in 1998, 1993, and 1989 [J].
Centorrino, F ;
Eakin, M ;
Bahk, WM ;
Kelleher, JP ;
Goren, J ;
Salvatore, P ;
Egli, S ;
Baldessarini, RJ .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (11) :1932-1935
[6]   The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis [J].
Emsley, R ;
Rabinowitz, J ;
Torreman, M .
SCHIZOPHRENIA RESEARCH, 2003, 61 (01) :47-57
[7]   Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations [J].
Freudenreich, O ;
Goff, DC .
ACTA PSYCHIATRICA SCANDINAVICA, 2002, 106 (05) :323-330
[8]   Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine [J].
Friedman, J ;
Ault, K ;
Powchik, P .
BIOLOGICAL PSYCHIATRY, 1997, 42 (06) :522-523
[9]   Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998-2000 [J].
Ganguly, R ;
Kotzan, JA ;
Miller, LS ;
Kennedy, K ;
Martin, BC .
JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (10) :1377-1388
[10]   CONCOMITANT USE OF THIORIDAZINE WITH RISPERIDONE [J].
GOSS, JB .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1995, 52 (09) :1012-1012